← Russell 3000 cross-section

STOK Stoke Therapeutics, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-03, not restated
Healthcare

Scale

Market cap
$2.1bn
Revenue TTM
$28m
Net income TTM
$-208m
Free cash flow
$-181m
Composite score
29.2
Sector rank
#1615

Valuation

P / E
EV / EBITDA
EV / sales
65.4
FCF yield
-8.62%
Earnings yield vs 10-yr
-14.65pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-753.6%
EBITDA margin
-803.4%
ROE
-60.2%
ROIC
-423.6%
Revenue growth
-86.2%

Insider activity, last 90 days

Net open-market
$-1.19m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Lease terms are triple net lease commencing at $ 0.9 million per year, then with 3 % annual base rent increases plus operating expenses, real estate taxes, utilities and janitorial fees. Lease terms commence at $ 0.7 million per annum, with 2.0 % annual base rent increases plus operating expenses, real estate taxes, and utilities. The Company is eligible to receive up to $ 245.0 million in potential total milestone payments based upon the achievement of certain development, regulatory, first commercial sales and sales milestone events for the SYNGAP1 program, assuming each milestone were achieved at least once. …Stoke Therapeutics, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-03

Read the full passage →